Nicolas U. Gerber
0000-0002-1783-631X
Publication & Citation Trends
Publications
0 total
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Cited by 2
Semantic Scholar
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Cited by 0
Semantic Scholar
The gut microbiome in pediatric diffuse midline gliomas: Correlative study results from the PNOC022 trial.
Cited by 0
Semantic Scholar
BIOM-43. SOMATICTP53, PIK3R1, NF1 ORTERT MUTATIONS ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOME IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL STUDY
Cited by 0
Semantic Scholar
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma OA
Cited by 17
Semantic Scholar
NCOG-05. HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Cited by 0
Semantic Scholar
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial OA
Cited by 18
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(149)
Neuroblastoma Research and Treatments
(69)
Childhood Cancer Survivors' Quality of Life
(24)
Testicular diseases and treatments
(22)
Brain Metastases and Treatment
(19)
Affiliations
Boston Children's Hospital
Lurie Children's Hospital
University of Bonn
Radboud University Nijmegen
Universität Hamburg